e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly
Pei-Chun Chan, Pin-Hui Lee, Min-Ju Lu, You-Chieh Huang, Teng-Yi Feng, Wen-Wen Chen, Chia-Chi Lee, Yen-Fang Huang, Chen-Yuan Chiang
Source:
Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018
Journal Issue:
March
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Pei-Chun Chan, Pin-Hui Lee, Min-Ju Lu, You-Chieh Huang, Teng-Yi Feng, Wen-Wen Chen, Chia-Chi Lee, Yen-Fang Huang, Chen-Yuan Chiang. Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly. Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Outcomes of treatment of latent tuberculosis infection in children with two different regimens
Source: Eur Respir J 2006; 28: Suppl. 50, 487s
Year: 2006
Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children
Source: Eur Respir J 2004; 24: Suppl. 48, 648s
Year: 2004
Efficiency of treatment regimens for chronic tuberculosis patients
Source: Eur Respir J 2003; 22: Suppl. 45, 519s
Year: 2003
Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment
Source: Annual Congress 2007 - Clinical tuberculosis
Year: 2007
Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population
Source: Eur Respir J 2005; 26: Suppl. 49, 624s
Year: 2005
Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019
Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study
Source: Eur Respir J, 52 (6) 1801470; 10.1183/13993003.01470-2018
Year: 2018
Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline
Source: International Congress 2019 – Tuberculosis: a public health approach
Year: 2019
The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Bedaquiline in the treatment of patients with co-infection HIV/tuberculosis
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis
Source: Eur Respir J , 49 (3) 1601799; DOI: 10.1183/13993003.01799-2016
Year: 2017
Long-term results of treatment with bedaquiline in patients with drug-resistant tuberculosis
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020
The efficacy of treatment of patients with drug resistant tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 661s
Year: 2007
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients
Source: Eur Respir J 2001; 18: Suppl. 33, 340s
Year: 2001
A choice of regimen improves completion for patients with latent TB infection
Source: Breathe 2008; 4: 366
Year: 2008
The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Efficacy of linezolide-free chemotherapy schemes in patients with highly drug-resistant tuberculosis
Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis
Year: 2021
Efficacy of a standard chemotherapy regimen in the management of sputum-positive pulmonary TB relapses
Source: Eur Respir J 2003; 22: Suppl. 45, 41s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept